Sandeep Dhindsa

ORCID: 0000-0001-9342-9807
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hormonal and reproductive studies
  • Pharmacology and Obesity Treatment
  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Muscle metabolism and nutrition
  • Hypothalamic control of reproductive hormones
  • Regulation of Appetite and Obesity
  • Diabetes and associated disorders
  • Adipokines, Inflammation, and Metabolic Diseases
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Pancreatic function and diabetes
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Diet and metabolism studies
  • Stress Responses and Cortisol
  • Sexual Differentiation and Disorders
  • Peroxisome Proliferator-Activated Receptors
  • Cardiac Imaging and Diagnostics
  • Coronary Interventions and Diagnostics
  • Cardiovascular Function and Risk Factors
  • Adipose Tissue and Metabolism
  • Asthma and respiratory diseases
  • Liver Disease Diagnosis and Treatment
  • NF-κB Signaling Pathways
  • Endoplasmic Reticulum Stress and Disease

Saint Louis University Hospital
2024-2025

Saint Louis University
2017-2024

UCLouvain Saint-Louis Brussels
2022-2024

University at Buffalo, State University of New York
2010-2022

Kaleida Health
2004-2018

Texas Tech University Health Sciences Center
2014-2018

Texas Tech University
2014-2018

Williams (United States)
2018

The Royal Wolverhampton NHS Trust
2017

Guy's and St Thomas' NHS Foundation Trust
2015

To test the possible acute proinflammatory effects of fatty acids, we induced an increase in plasma free acid (FFA) concentrations after a lipid and heparin infusion for 4 h 10 healthy subjects. We determined nuclear factor-kappaB (NF-kappaB) binding activity mononuclear cells (MNCs), p65 subunit NF-kappaB, reactive oxygen species (ROS) generation by MNC, polymorphonuclear leukocytes (PMN). Brachial artery reactivity, using postischemic flow-mediated dilation, was also measured. NF-kappaB...

10.2337/diabetes.52.12.2882 article EN Diabetes 2003-12-01

Type 2 diabetes is associated with lower total testosterone (T) levels in cross-sectional studies. However, it not known whether the defect primary or secondary. We investigated prevalence of hypogonadism type by measuring serum T, free T (FT), SHBG, LH, FSH, and prolactin (PRL) 103 patients. FT was measured equilibrium dialysis. also calculated using SHBG (cFT). Hypogonadism defined as low cFT. The mean age 54.7 +/- 1.1 yr, body mass index (BMI) 33.4 0.8 kg/m(2), HbA1c 8.4 0.2%. 12.19 0.50...

10.1210/jc.2004-0804 article EN The Journal of Clinical Endocrinology & Metabolism 2004-11-01

We have recently demonstrated a potent antiinflammatory effect of troglitazone, an agonist peroxisome proliferator-activated receptor γ (PPARγ) and partial PPARα in both the nondiabetic obese diabetic subjects. now investigated actions rosiglitazone, selective PPARγ agonist. Eleven subjects 11 were each given 4 mg rosiglitazone daily for period 6 wk. Fasting blood samples obtained at 0, 1, 2, 4, 6, 12 wk (6 after cessation rosiglitazone). Eight five also included study as control groups....

10.1210/jc.2003-032103 article EN The Journal of Clinical Endocrinology & Metabolism 2004-06-01

OBJECTIVE To determine the prevalence of subnormal testosterone concentrations in patients with obesity and type 2 diabetes a primary care clinic population. RESEARCH DESIGN AND METHODS Free 1,849 men (1,451 nondiabetic 398 diabetic) Hypogonadism In Males (HIM) study were analyzed. The HIM was U.S.-based cross-sectional designed to define hypogonadism aged >45 years. measured by equilibrium dialysis. RESULTS free lean, overweight, obese 26% (n = 275), 29% 687), 40% 489), respectively...

10.2337/dc09-1649 article EN cc-by-nc-nd Diabetes Care 2010-03-03

OBJECTIVE One-third of men with type 2 diabetes have hypogonadotropic hypogonadism (HH). We conducted a randomized placebo-controlled trial to evaluate the effect testosterone replacement on insulin resistance in and HH. RESEARCH DESIGN AND METHODS A total 94 were recruited into study; 50 eugonadal, while 44 had Insulin sensitivity was calculated from glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp. Lean body mass fat measured by DEXA MRI. Subcutaneous samples taken...

10.2337/dc15-1518 article EN Diabetes Care 2015-11-30

Our objective was to determine whether exenatide exerts an antiinflammatory effect.Twenty-four patients were prospectively randomized be injected sc with either 10 μg twice daily [n = 12; mean age 56 ± 3 yr; body mass index 39.8 2 kg/m(2); glycosylated hemoglobin (HbA1c) 8.6 0.4%] or placebo (n 54 4 39.1 1.6 HbA1c 8.5 0.3%) for 12 wk. Fasting blood samples obtained at 0, 3, 6, and Blood also collected up 6 h after a single dose of (5 μg) placebo.Fasting glucose fell from 139 17 110 9 mg/dl,...

10.1210/jc.2011-1508 article EN The Journal of Clinical Endocrinology & Metabolism 2011-10-20

Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus, sitagliptin increases their bioavailability. The stimulation insulin suppression glucagon secretion that follow exert a glucose lowering effect hence its use as antidiabetic drug. Because DPP-IV expressed CD26 on cell membranes because mediates proinflammatory signals, we hypothesized may antiinflammatory...

10.1210/jc.2012-1544 article EN The Journal of Clinical Endocrinology & Metabolism 2012-06-29

<h3>Importance</h3> Male sex is a risk factor for developing severe COVID-19 illness. It not known whether hormones contribute to this predisposition. <h3>Objective</h3> To investigate the association of concentrations serum testosterone, estradiol, and insulinlike growth 1 (IGF-1, which are regulated by hormone signaling) with severity. <h3>Design, Setting, Participants</h3> This prospective cohort study was conducted using samples collected from consecutive patients who presented March...

10.1001/jamanetworkopen.2021.11398 article EN cc-by-nc-nd JAMA Network Open 2021-05-25

We have previously shown that hypogonadotrophic hypogonadism is common in middle-aged patients with type 2, but not 1, diabetes. now investigated the total and free testosterone concentrations young (aged 18-35 years) 1 2 diabetic patients.In this study carried out a tertiary referral center, serum of were measured 38 (mean age 26.45 +/- 0.89 24 27.87 0.97 subjects. The mean BMI was 27.41 1.18 38.55 2.04 kg/m(2), respectively (P < 0.001).The concentration 22.89 1.23 11.14 0.99 nmol/l,...

10.2337/dc08-0851 article EN cc-by-nc-nd Diabetes Care 2008-07-24

To determine whether the addition of liraglutide to insulin treat patients with type 1 diabetes leads an improvement in glycemic control and diminish variability.In this study, 14 well-controlled on continuous glucose monitoring intensive therapy were treated for week. Of patients, eight continued 24 weeks.In all mean fasting weekly concentrations significantly decreased after week from 130±10 110±8 mg/dl (P<0.01) 137.5±20 115±12 respectively. Glycemic excursions improved at The s.d. 56±10...

10.1530/eje-11-0330 article EN European Journal of Endocrinology 2011-06-07

It has been suggested that the high prevalence of subnormal free testosterone concentrations, along with low or inappropriately normal gonadotropins in men type 2 diabetes, may be result an increase plasma estradiol concentrations secondary to aromatase activity adipose tissue leads suppression hypothalamo-hypophyseal-gonadal axis.To investigate this hypothesis, estradiol, testosterone, leutinizing hormone, follicle-stimulating and sex hormone-binding globulin (SHBG) were measured fasting...

10.2337/dc11-0208 article EN cc-by-nc-nd Diabetes Care 2011-06-30

After the demonstration that one-third of male patients with type 2 diabetes have hypogonadotrophic hypogonadism, we shown hypogonadism also markedly elevated C-reactive protein (CRP) concentrations. We now hypothesized diabetic subjects may a lower hematocrit because testosterone stimulates, whereas chronic inflammation suppresses, erythropoiesis.Seventy at tertiary referral center were included in this study.The mean (n = 37), defined as calculated free (cFT) <6.5 ng/dl, was 40.6 +/- 1.1%,...

10.2337/dc06-0637 article EN Diabetes Care 2006-09-26

To investigate whether addition of three different doses liraglutide to insulin in patients with type 1 diabetes (T1D) results significant reduction glycemia, body weight, and dose.We randomized 72 (placebo = 18, 54) T1D receive placebo 0.6, 1.2, 1.8 mg daily for 12 weeks.In the 1.2-mg 1.8-mg groups, mean weekly average blood glucose was -0.55 ± 0.11 mmol/L (10 2 mg/dL) 0.05 mg/dL), respectively (P < 0.0001), while it remained unchanged 0.6-mg groups. In group, HbA1c fell significantly...

10.2337/dc15-1136 article EN Diabetes Care 2016-04-05

Obesity in adult males is associated with hypogonadotropic hypogonadism. We evaluated the effect of obesity on plasma testosterone concentrations pubertal and post-pubertal young males.Morning fasting blood samples were obtained from 25 obese [body mass index (BMI) ≥95th percentile] lean (BMI <85th percentile) between ages 14-20 years Tanner staging ≥4. Total (TT) free (FT) estradiol measured by liquid chromatography tandem spectrometry equilibrium dialysis. Free was also calculated using...

10.1111/cen.12018 article EN Clinical Endocrinology 2012-09-13

To investigate whether testosterone therapy (TTh) in men with hypogonadism and type 2 diabetes mellitus (T2DM) improves glycaemic control insulin sensitivity, results remission of T2DM.A total 356 who had levels ≤12.1 nmol/L (350 ng/dL) symptoms were included the study followed up for 11 years. All patients received standard treatment 178 additionally parenteral undecanoate 1000 mg every 12 weeks following an initial 6-week interval. A group comprised hypogonadal opted not to receive...

10.1111/dom.14122 article EN cc-by-nc Diabetes Obesity and Metabolism 2020-06-19

e have recently reported (1) that male patients with type 2 diabetes frequent hypogonadotrophic hypogonadism.We now asked whether a similar defect may be observed in 1 diabetic males to determine per se is the cause of hypogonadism.

10.2337/dc06-0197 article EN Diabetes Care 2006-05-01
Coming Soon ...